236 related articles for article (PubMed ID: 17669010)
1. Improving vaccines by incorporating immunological coadjuvants.
Fraser CK; Diener KR; Brown MP; Hayball JD
Expert Rev Vaccines; 2007 Aug; 6(4):559-78. PubMed ID: 17669010
[TBL] [Abstract][Full Text] [Related]
2. The role of adjuvants in the development of mucosal vaccines.
Vajdy M; Singh M
Expert Opin Biol Ther; 2005 Jul; 5(7):953-65. PubMed ID: 16018740
[TBL] [Abstract][Full Text] [Related]
3. Improving vaccine delivery using novel adjuvant systems.
Pichichero ME
Hum Vaccin; 2008; 4(4):262-70. PubMed ID: 18398303
[TBL] [Abstract][Full Text] [Related]
4. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
Lawson LB; Norton EB; Clements JD
Curr Opin Immunol; 2011 Jun; 23(3):414-20. PubMed ID: 21511452
[TBL] [Abstract][Full Text] [Related]
5. Jump-starting the immune system: prime-boosting comes of age.
Woodland DL
Trends Immunol; 2004 Feb; 25(2):98-104. PubMed ID: 15102369
[TBL] [Abstract][Full Text] [Related]
6. Delivery systems for molecular vaccination.
Sheikh NA; al-Shamisi M; Morrow WJ
Curr Opin Mol Ther; 2000 Feb; 2(1):37-54. PubMed ID: 11249651
[TBL] [Abstract][Full Text] [Related]
7. Microparticles as vaccine adjuvants and delivery systems.
O'Hagan DT; Singh M
Expert Rev Vaccines; 2003 Apr; 2(2):269-83. PubMed ID: 12899577
[TBL] [Abstract][Full Text] [Related]
8. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.
Garçon N; Van Mechelen M
Expert Rev Vaccines; 2011 Apr; 10(4):471-86. PubMed ID: 21506645
[TBL] [Abstract][Full Text] [Related]
9. Innate immunity and new adjuvants.
Mutwiri G; Gerdts V; Lopez M; Babiuk LA
Rev Sci Tech; 2007 Apr; 26(1):147-56. PubMed ID: 17633299
[TBL] [Abstract][Full Text] [Related]
10. [Adjuvants as factors improving efficiency of vaccination].
Chodaczek G
Postepy Hig Med Dosw (Online); 2004 Mar; 58():47-59. PubMed ID: 15069382
[TBL] [Abstract][Full Text] [Related]
11. Immunity in response to particulate antigen-delivery systems.
Storni T; Kündig TM; Senti G; Johansen P
Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945
[TBL] [Abstract][Full Text] [Related]
12. Adjuvants may reduce in vivo transfection levels for DNA vaccination in mice leading to reduced antigen-specific CD8+ T cell responses.
Rose AH; Hoffmann FW; Hara JH; Urschitz J; Moisyadi S; Hoffmann PR; Bertino P
Hum Vaccin Immunother; 2015; 11(9):2305-11. PubMed ID: 26091088
[TBL] [Abstract][Full Text] [Related]
13. Generation of improved mucosal vaccines by induction of innate immunity.
Lavelle EC
Cell Mol Life Sci; 2005 Dec; 62(23):2750-70. PubMed ID: 16237500
[TBL] [Abstract][Full Text] [Related]
14. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
De Magistris MT
Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
[TBL] [Abstract][Full Text] [Related]
15. Translating innate immunity into immunological memory: implications for vaccine development.
Pulendran B; Ahmed R
Cell; 2006 Feb; 124(4):849-63. PubMed ID: 16497593
[TBL] [Abstract][Full Text] [Related]
16. Mucosal immunisation: adjuvants and delivery systems.
Moyle PM; McGeary RP; Blanchfield JT; Toth I
Curr Drug Deliv; 2004 Oct; 1(4):385-96. PubMed ID: 16305400
[TBL] [Abstract][Full Text] [Related]
17. [Adjuvants--essential components of new generation vaccines].
Dzierzbicka K; Kołodziejczyk AM
Postepy Biochem; 2006; 52(2):204-11. PubMed ID: 17078510
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory properties of the vaccine adjuvant alum.
Oleszycka E; Lavelle EC
Curr Opin Immunol; 2014 Jun; 28():1-5. PubMed ID: 24463269
[TBL] [Abstract][Full Text] [Related]
19. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.
Didierlaurent AM; Collignon C; Bourguignon P; Wouters S; Fierens K; Fochesato M; Dendouga N; Langlet C; Malissen B; Lambrecht BN; Garçon N; Van Mechelen M; Morel S
J Immunol; 2014 Aug; 193(4):1920-30. PubMed ID: 25024381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
